The full report of the results of the LILAC-2 study has been published this week -
Trofinetide for the treatment of Rett syndrome: long-term safety and efficacy results from the open-label LILAC-2 study
This was one of the presentations made by Acadia at the recent IRSF Scientific Meeting.
The full report of the results of the LILAC-2 study has been...
-
- There are more pages in this discussion • 145 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 555 | $17.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1600 | 1 |
View Market Depth
| Last trade - 13.09pm 07/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable